Participated · Series B · Oct 2022

Resolve Biosciences applies its proprietary Molecular Cartography technology to provide the highest-resolution view of subcellular, single-molecule biology. Its fully automated, highly multiplexed single-molecule FISH workflow delivers three-dimensional spatial context at subcellular resolution while preserving tissue samples. The platform emphasizes sensitivity, specificity, and workflow convenience for basic, translational, and clinical research and has been cited in peer-reviewed publications. The underlying technology is modular and expected to incorporate interrogation of DNA, protein, and metabolomic data layers in the future. Resolve has commercially installed workflows at multiple leading European and North American laboratories and intends to scale operations worldwide. The company secured a $71 million Series B and has now raised more than $100 million to accelerate product development and meet growing demand. Resolve Biosciences offers a Molecular Cartography platform that provides multi-analyte, highly multiplex spatial analysis at subcellular resolution while preserving sample tissue. The platform uses proprietary multiplexed single-molecule detection to deliver deep contextual transcriptomic data and can interrogate hundreds of genes in a single run. Resolve positions the technology for applications in oncology, neuroscience, and infectious disease, emphasizing sensitivity, specificity, and workflow convenience. Future solutions aim to add DNA, protein, and metabolomic data layers to the platform. The technology has been under development since 2016 and is currently available through an oversubscribed early access program. The company is privately held and headquartered in Monheim am Rhein, Germany, and recently completed a financing to accelerate product development and industry adoption.

Participated · Equity · Apr 2021

Edifice Health applies novel proteomic approaches combined with proprietary artificial intelligence and predictive analysis to measure the rate at which an individual’s body ages. The company created a metric to measure systemic chronic inflammation, which Stanford Project research identified as a root cause and predictor of multiple chronic diseases of aging. Edifice has identified interventional supplements that can be targeted to an individual’s immunotype to improve inflammatory health and support healthy aging. The company was born out of the Stanford 1,000 Immunomes Project following NIH-funded research in immunological health and aging at Stanford University. Led by Chairman and CEO Wolfgang Daum, PhD, with founder David Furman, PhD active on the board, Edifice is building its scientific foundation and product capabilities. The company intends to use the new funding to grow its immunological science and add additional talent.

Participated · Series C · May 2016

Founded in 2009, Bolt Threads develops spider-silk materials produced by engineered microorganisms. Its first commercial product was a $314 necktie launched in early 2017, and the company has partnerships with Patagonia and Stella McCartney and acquired Best Made Company. Bolt says it is the first to bring man-made spider silk to market and plans to continue refining its processes and pursuing additional brand partnerships and products slated for 2018. The company will use the new funding to continue development and commercialization of its microorganism-derived materials. Financially, Bolt has raised a total of $213 million to date, including the recent Series D. Bolt Threads has developed a method to brew spider silk and other insect-derived fibers and spin them into yarn, making those materials accessible to apparel and upholstery manufacturers. The company was co-founded in 2009 by CEO Dan Widmaier, Chief Scientific Officer David Breslauer and VP of Operations Ethan Mirsky. Bolt already manufactures its Engineered Silk protein at scale via outsourced manufacturing partners and plans to move into yarn manufacturing in the summer. The company said it has built much of the supply chain and is in the process of scaling up to bring products to market. Bolt also inked a deal with Patagonia to begin developing and designing products using its fibers, though specific product details were not disclosed. Investors and company leadership expect the biofabricated silks to become available in mainstream products by 2018. Bolt Threads engineers microbes to produce spider-silk proteins and spin them into high-performance fibers. The company says the material can be stronger than steel, softer than Merino wool, washable, dyeable and UV resistant, offering a sustainable alternative to polyester. Bolt is targeting textile and apparel applications and is working with large textile partners while also planning its own consumer product line. The team includes co-founder and CEO Dan Widmaier alongside scientists David Breslauer and Ethan Mirsky; the company had been operating in stealth prior to the raise. Bolt aims to commercialize scalable production of the fiber and bring cloth to both manufacturers and the public by 2016. The company positions the technology as a more eco-friendly solution for the clothing industry’s pollution and performance-fiber needs.

Participated · Series C · May 2012

Assurex Health offers GeneSight, a treatment-decision-support test powered by CPGx™, its proprietary combinatorial pharmacogenomics technology, which measures multiple genomic variants and weights them together to provide genetically-driven medication information for each patient. The company recently enhanced the GeneSight Psychotropic test to give providers an expanded range of options for treating depression, anxiety, bipolar disorder, PTSD, schizophrenia and other behavioral health conditions. To date more than 14,000 healthcare providers have used GeneSight to help make treatment decisions for over 230,000 patients across the country. Led by President and CEO Virginia C. Drosos, Assurex will use additional funding to continue to increase adoption of GeneSight. The company also serves chronic pain conditions through its treatment decision support offerings. Assurex Health provides healthcare providers with GeneSight, a treatment decision‑support platform that analyzes how a patient’s genetics affect responses to medications for behavioral health and chronic pain. GeneSight evaluates a patient’s cheek swab against over 785,000 genetic–medication permutations and reports on 38 FDA‑approved medications across depression, PTSD, bipolar disorder, schizophrenia and other mental health conditions. Results are delivered in an actionable color‑coded report available 36 hours after Assurex receives a patient sample. The company also offers financial assistance programs for eligible patients. Led by President and CEO Virginia C. Drosos, Assurex is using proceeds from a $30M equity financing to support increased clinical adoption and further development of its GeneSight products. Assurex Health is a Mason, OH–based personalized medicine company that provides clinically-relevant individualized genetic information to help physicians select medications for depression, anxiety, chronic pain, ADHD and other neuropsychiatric disorders. Its core product is the GeneSight® suite, built on proprietary pharmacogenomics technology combined with evidence-based medicine and clinical pharmacology. The company has licensed patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center. Led by CEO James S. Burns, Assurex intends to use the proceeds from its financing to support increasing clinical adoption of its GeneSight products. The company secured a $32M financing comprising a $25M term and revolving credit facility and a $7M equity financing from existing investors.